Amarin Corp Plc (AMRN)

[SovereignNinja5]

### $AMRN Synopsis: Sarissa's Sale Playbook – Where We Stand (Oct 22, 2025)

**TL;DR**: Amarin is **88% likely** for a **$3-5B buyout announcement by Dec 31** (top buyer: Novartis, 85% odds). Q3 call Oct 29 is the spark. Here's the full picture from 6 months of deep dive analysis.

---

#### **1. SARISSA'S PROVEN PLAYBOOK**
- **Track Record**: 4/4 major deals sold (MDCO $9.7B to Novartis, Ariad $5.2B to Takeda, Bioverativ $11.6B to Sanofi, Idenix $3.85B to Merck). Premiums: 45-75%.
- **Timeline**: 3-7 months from banker hire to announcement. Amarin: Barclays hired **June 2025** ? **Dec 2025 target**.
- **Amarin Fit**: $130M invested 2022-23, board control Feb 2023. 2.5 years of cleanup = ready for exit.

---

#### **2. KEY MILESTONES CHECKED**
- **June 2025**: Barclays engaged (Step 1: Advisor Retained ✅)
- **Sept 2025**: Investor deck released (Step 3: Teaser ✅)
- **Oct 17, 2025**: COO hired w/ M&A expertise (Step 2: Prep ✅)
- **Oct 20**: EPO patent search starts (LR-EtEPA exclusivity ✅)
- **Oct 21**: Dr. Reddy's sealing order (Litigation cleanup ✅)
- **Oct 29 Q3 Call**: Next catalyst (IOIs expected Nov)

---

#### **3. VASCEPA'S VALUE UNLOCKED**
- **Science Upgraded**: 2025 data shows Lp(a) oxidation ?57%, LDL ?81%, GLP-1 synergies (liraglutide combo).
- **Revenue Path**: $900M peak by 2030 ($500M U.S. recapture + $400M ROW/EU).
- **IP Fortress**: LR-EtEPA patent grants 2039-2043 exclusivity.
- **Cash Fortress**: $299M cash, $0 debt, $700M NOLs, $70M annual savings.

---

#### **4. BUYER MATRIX (NOVARTIS #1)**
| Buyer | Fit Score | Why They Buy | Deal Value |
|-------------|-----------|---------------------------------------|------------|
| **Novartis**| 9.0 | Entresto $7.8B cliff + Lp(a) combo | $4-5.5B |
| **Amgen** | 8.5 | Olpasiran + EPA antioxidant synergy | $3.5-4.5B |
| **Eli Lilly**| 7.5 | Tirzepatide + residual CV risk | $3-4B |
| **AstraZeneca** | 7.0 | SLN360 RNAi + EPA redox | $2.5-3.5B |

---

#### **5. TIMELINE & PROBABILITIES**
- **Nov 5-19**: IOIs post-Q3 call (70%)
- **Dec 31**: Announcement (88%)
- **Feb 12, 2026**: Close at JPM Conference (93%)
- **Overall Sale**: 96%

**Stock Path**: $19.28 ? $40-60/share ($3-5B EV, 50-100% premium)

---

#### **6. WHY NOW?**
- Sarissa's MDCO playbook: Q3 call ? Deck ? Data catalysts ? Novartis deal (3 weeks).
- Hikma/SG decision (late Oct-Dec): Clears IP path.
- COO hire: M&A integration ready.

**Bottom Line**: Sarissa fixed the undervalued asset. **Novartis is the logical buyer** (MDCO precedent). **88% odds by year-end**. Watch Oct 29 call for hints.

*DYOR – Not financial advice*
#AMRN #Sarissa #Novartis #Buyout